Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Arcus Biosciences, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 200
- +19 vs. Q3 2022
- Shares held
- 53.8M
- +1.31M (+2.5%) vs. Q3 2022
- Total value
- $1.11B
- −$260.6M (−19.0%) vs. Q3 2022
- New holders
- 41
- 74 more added
- Sold out
- 22
- 64 more reduced
2 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RCUS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 231 | $3.78B |
| Q1 2026 | 211 | $2.57B |
| Q4 2025 | 209 | $2.89B |
| Q3 2025 | 190 | $1.37B |
| Q2 2025 | 186 | $811.5M |
| Q1 2025 | 187 | $763.3M |
| Q4 2024 | 186 | $1.25B |
| Q3 2024 | 187 | $815.7M |
| Q2 2024 | 193 | $790.9M |
| Q1 2024 | 172 | $997.7M |
| Q4 2023 | 185 | $1.01B |
| Q3 2023 | 187 | $947.9M |
| Q2 2023 | 181 | $1.11B |
| Q1 2023 | 180 | $1.01B |
| Q4 2022 | 200 | $1.11B |
| Q3 2022 | 183 | $1.37B |
| Q2 2022 | 173 | $1.33B |
| Q1 2022 | 157 | $1.60B |
| Q4 2021 | 142 | $2.06B |
| Q3 2021 | 131 | $1.68B |
| Q2 2021 | 130 | $1.24B |
| Q1 2021 | 148 | $1.25B |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Arcus Biosciences, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −666,477−100.0% | Sold out |
| Finepoint Capital LP | 0 | $0 | 0.00% | −646,586−100.0% | Sold out |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −303,000−100.0% | Sold out |
| Endurant Capital Management LP | 0 | $0 | 0.00% | −97,327−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −49,891−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −38,725−100.0% | Sold out |
| AlphaCrest Capital Management LLC | 0 | $0 | 0.00% | −35,523−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −29,867−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −28,451−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −9,880−100.0% | Sold out |
| Personal Capital Advisors Corp | 0 | $0 | 0.00% | −9,395−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −8,771−100.0% | Sold out |
| NinePointTwo Capital | 0 | $0 | 0.00% | −8,732−100.0% | Sold out |
| Diversified Trust Co | 0 | $0 | 0.00% | −8,645−100.0% | Sold out |
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −8,500−100.0% | Sold out |
| Cornercap Investment Counsel Inc | 0 | $0 | 0.00% | −8,138−100.0% | Sold out |
| Neuberger Berman Group LLC | 0 | $0 | 0.00% | −7,837−100.0% | Sold out |
| MML Investors Services, LLC | 0 | $0 | 0.00% | −7,741−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −5,833−100.0% | Sold out |
| Islay Capital Management, LLC | 0 | $0 | 0.00% | −1,776−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Wipfli Financial Advisors LLC, | – | – | – | – | Not filed |
| New Century Advisors, LLC | – | – | – | – | Not filed |